TL;DR
Findings indicate that insulin increases NF-κB activation in doxorubicin -treated T-47D breast cancer cells and may sustain NF-κB activity against the cytotoxic effects of doxorubicin.
Findings indicate that insulin increases NF-κB activation in doxorubicin-treated T-47D breast cancer cells and may sustain NF-κB activity against the cytotoxic effects of doxorubicin.
Insulin affects the viability of Luminal A breast cancer T-47D cells exposed to doxorubicin, indicating reduced cellular sensitivity to the cytotoxic effects of doxorubicin.
Insulin affects the viability of Luminal A breast cancer T-47D cells exposed to doxorubicin, indicating reduced cellular sensitivity to the cytotoxic effects of doxorubicin.
It is demonstrated that VPA enhances the radiosensitivity of breast tumor by activating the βTrCP-NF-κB immune pathway, which reprograms tumor-associated macrophages (TAMs) into the M1 phenotype, revealing a novel immunological mechanism for its application as a RT adjuvant.
Findings identify heat-labile, NET-associated components as mediators of breast cancer chemoresistance and support targeting NETs or their downstream signaling pathways to improve chemotherapy response.
Investigating the effects of metformin on key inflammatory cytokines involved in hepatocellular carcinoma progression, as well as on the expression of c-Jun, a key subunit of the AP-1, led to a significant reduction in the levels of IL-6 and IL-8 in HepG2 cells compared to control group.
We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.
